Amgen to Showcase Biotechnology Innovations at TD Cowen Health Care Conference 2026

Amgen to Present at Upcoming Health Care Conference, Highlighting Commitment to Biotechnology Innovation

Amgen, a prominent biotechnology firm firmly rooted in Thousand Oaks, California, is set to present at the 46th Annual TD Cowen Health Care Conference on March 2, 2026. The presentation will feature key insights from Kave Niksefat, the company's senior vice president of Global Marketing and Access, alongside Justin Claeys, senior vice president of Finance. This event underscores Amgen's ongoing commitment to share its developments and innovations in the biotechnology sector with a broader audience, particularly as the industry continues to evolve rapidly. Attendees can access the presentation via a live webcast, which will be available for replay on Amgen's website for 90 days after the event, ensuring that stakeholders and interested parties can stay informed.

As a leader in biotechnology, Amgen has made significant strides in developing treatments across various medical fields, including cancer, heart disease, and rare diseases. By leveraging advanced biology and cutting-edge technology, Amgen focuses on creating impactful medicines that address critical health challenges faced by millions of patients worldwide. The company’s relentless pursuit of innovation and quality in its therapeutic offerings has reinforced its pivotal role in the biotechnology landscape, shaping the future of medicine. Amgen's ability to navigate complex scientific challenges has not only propelled its therapeutic advancements but has also ensured its competitive edge within the industry.

Moreover, Amgen's reputation is further exemplified by its inclusion in the Dow Jones Industrial Average® and the Nasdaq-100 Index®, which reflects its significant market capitalization and influence among innovative firms. The company is also recognized for its outstanding workplace culture and innovation, receiving accolades from respected sources such as Fast Company and Forbes. This recognition highlights Amgen's dedication to fostering a collaborative environment that promotes creativity and excellence. As the biotechnology sector continues to grow, Amgen remains committed to its mission of delivering transformative therapies that enhance patient lives while upholding high standards of workplace engagement and innovation.

In addition to the upcoming conference, Amgen emphasizes the importance of transparent communication and encourages stakeholders to follow their updates through the company website and social media channels. For inquiries related to media and investors, Amgen has provided comprehensive contact details, reinforcing its commitment to maintaining an open dialogue with its community. This proactive approach positions Amgen as a forward-thinking leader in the biotechnology sector, continuously seeking to improve health outcomes while engaging actively with its audience.